Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Trial Details
- NCT ID
- NCT07085559
- Phase
- EARLY_PHASE1
- Sponsor
- Anhui Provincial Hospital
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Metabolically Armed BCMA CAR-T cells.
- Locations (sample)
- Hefei, Anhui, China|31.86389,117.28083
Key Eligibility Criteria
- Age 19 to 75 years old, male or female. The subject or his/her guardian voluntarily signed the informed consent;
- Subjects with relapsed or refractory Plasma Cell Neoplasms（including Multiple Myeloma, Plasma Cell Leukemia, AL Amyloidosis）according to IMWG crite…
- Evidence of cell membrane BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue.
- The subjects were unable to receive autologous hematopoietic stem cell transplantation treatment, or relapsed after autologous hematopoietic stem c…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →